Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by L. Yu
Total Records ( 3 ) for L. Yu
  Y Huang , L Li and L. Yu

X-ray repair cross-complementing group 1 (XRCC1) plays an important role in base excision and single-strand break repair, as a scaffold protein that brings together proteins of the DNA repair complex, and appears to be a candidate for cancer risk. However, studies on the association between polymorphisms in this protein and cancer have yielded conflicting results. We performed a meta-analysis to investigate the association between the breast cancer and the XRCC1 polymorphisms Arg194Trp (9411 cases and 9783 controls), Arg399Gln (22 481 cases and 23 905 controls) and Arg280His (6062 cases and 5864 controls) in different inheritance models. Our analysis suggested that Arg399Gln was associated with a trend of increased breast cancer risk when using both dominant [odds ratio (OR) = 1.06, 95% confidence interval (CI): 1.00–1.13] and recessive models (OR = 1.12, 95% CI: 1.02–1.23) to analyse the data. In ethnic subgroups and using recessive model analysis: Arg399Gln increased breast cancer risk in Asians (OR = 1.26, 95% CI: 0.96–1.64) and Africans (OR = 1.80, 95% CI: 0.97–3.32), and also while only slightly increasing the breast cancer risk in Caucasians (OR = 1.08, 95% CI: 0.95–1.22). However, Arg194Trp (recessive model, OR = 0.95, 95% CI: 0.75–1.20) and Arg280His (recessive model, OR = 1.28, 95% CI: 0.64–2.55) did not appear to be risk factors for breast cancer. Larger scale primary studies are required to further evaluate the interaction of XRCC1 polymorphisms and breast cancer risk in specific populations.

  B Peng , L Cao , W Wang , L Xian , D Jiang , J Zhao , Z Zhang , X Wang and L. Yu

Matrix metalloproteinase (MMP) 1 and MMP3 are enzymes that degrade the extracellular matrix and have been implicated to play an important role in cancer development. Many studies have been carried out on the association between polymorphisms of MMP1 –1607 1G>2G and MMP3 –1171 5A>6A and cancer risk. However, results from these studies remain inconclusive. Here, we performed a meta-analysis of >38 000 subjects to better assess the purported associations. For MMP1, –1607 2G/2G genotype carriers were found to have an increased risk of colorectal cancer [2G/2G versus 2G/1G + 1G/1G, odds ratio (OR) = 1.48, 95% confidence interval (CI) (1.26–1.74), Pheterogeneity = 0.066, I2 = 49.3%], head and neck cancer [2G/2G versus 2G/1G + 1G/1G, OR = 1.61, 95% CI (1.26–2.07), Pheterogeneity = 0.002, I2 = 64.7%] and renal cancer [2G/2G versus 2G/1G + 1G/1G, OR = 1.82, 95% CI (1.38–2.39), Pheterogeneity = 0.589, I2 = 0.0%] risk. For MMP3, no association was found between –1171 5A>6A polymorphism and cancer risk in the overall group [6A versus 5A, OR = 1.00, 95% CI (0.95–1.05), Pheterogeneity = 0.124, I2 = 24.9%] and individual cancer subgroups, but stratified analysis by smoking status showed that this polymorphism had different effects on smokers and non-smokers under recessive genetic model. In summary, our study suggests that MMP1 –1607 2G may be associated with an increased cancer risk for certain types of cancers, MMP3 –1171 5A>6A may not be a major risk factor for cancer, but it may be modified by certain environmental factors. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.

  B Peng , L Cao , X Ma , W Wang , D Wang and L. Yu

Matrix metalloproteinase (MMP) 2, MMP7 and MMP9 are important members of the MMP family. Four polymorphisms in the promoter region of these MMPs, which are MMP2 –1306 C>T, MMP2 –735 C>T, MMP7 –181 A>G and MMP9 –1562 C>T, have been reported to be functional and may contribute to genetic susceptibility to cancers. However, the associations between these polymorphisms and cancer risk remain inconclusive due to conflicting results from different case–control studies. To better evaluate the role of these polymorphisms in cancer development, we conducted a meta-analysis that included 51 studies, with more than 40 000 subjects. The results showed that under dominant genetic model, MMP2 –1306 T was associated with lower susceptibility to lung cancer [odds ratio (OR) = 0.50, 95% confidence interval (CI) 0.43–0.59, Pheterogeneity = 0.147, I2 = 44.1%], head and neck cancer (OR = 0.53, 95% CI 0.41–0.69, Pheterogeneity = 0.974, I2 = 0.0%) and oesophageal cancer (OR = 0.67, 95% CI 0.55–0.80, Pheterogeneity = 0.593, I2 = 0.0%); MMP2-735T was associated with lower risk in lung cancer (OR = 0.65, 95%CI 0.53–0.79, Pheterogeneity = 0.42, I2 = 0.0%) and oesophageal cancer (OR = 0.84, 95% CI 0.70–0.99, Pheterogeneity = 0.206, I2 = 37.4%); MMP7 –181 AG and GG genotype carriers had an increased gastric cancer risk (OR = 1.90, 95% CI 1.43–2.51, Pheterogeneity = 0.992, I2 = 0.0%) and MMP9 –1562 C>T was not associated with cancer risk in the whole group analysis (OR = 0.99, 95% CI 0.91–1.08, Pheterogeneity = 0.419, I2 = 3.0%) and subgroup analyses. In all, our meta-analysis suggests that MMP2 –1306 C>T, MMP2 –735 C>T and MMP7 –181 A>G may play allele-specific roles in cancer development, while MMP9 –1562 C>T may not be a major risk factor for most cancer types. Large case–control studies should be performed to clarify the possible roles of these four polymorphisms in different kinds of cancer in more detail.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility